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Abstract
Nanomedicine has the potential to transform clinical care in the 21st century. However, a precise understanding of how
nanomaterial design parameters such as size, shape and composition affect the mammalian immune system is a
prerequisite for the realization of nanomedicine’s translational promise. Herein, we make use of the recently developed
Particle Replication in Non-wetting Template (PRINT) fabrication process to precisely fabricate particles across and the nano-
and micro-scale with defined shapes and compositions to address the role of particle design parameters on the murine
innate immune response in both in vitro and in vivo settings. We find that particles composed of either the biodegradable
polymer poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polyethylene glycol (PEG) do not cause release of
pro-inflammatory cytokines nor inflammasome activation in bone marrow-derived macrophages. When instilled into the
lungs of mice, particle composition and size can augment the number and type of innate immune cells recruited to the
lungs without triggering inflammatory responses as assayed by cytokine release and histopathology. Smaller particles
(806320 nm) are more readily taken up in vivo by monocytes and macrophages than larger particles (6 mm diameter), yet
particles of all tested sizes remained in the lungs for up to 7 days without clearance or triggering of host immunity. These
results suggest rational design of nanoparticle physical parameters can be used for sustained and localized delivery of
therapeutics to the lungs.
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Introduction
The application of nanoparticles in medicine for disease
treatment is a potentially transformative area of research. The
possibility of potent instruction and modulation of host physiology
through nanomaterials has been abundantly demonstrated. These
efforts include modulation of cell-specific gene expression through
delivery of antisense oligonucleotides, dose-sparing and targeted
delivery of pharmacologics, as well as enhanced multi-functional
imaging diagnostics through nanoformulations [1–3]. Another
area where nanotechnology may revolutionize clinical care is the
ability to direct immune responses in defined manners. The most
obvious benefit is in the design of next-generation vaccines against
microbial pathogens, whereby antigen specific immune responses
can be elicited at levels far more potent than existing vaccines,
commensurate with the immune response engendered by live
organisms [4–6]. These latter advances owe much to our recent
understanding of the critical role of innate immunity in
contextualizing an appropriate adaptive immune response. This
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context is triggered through endogenous host receptor signaling
pathways, most well characterized by the TLR family of pattern
recognition receptors (PRR), but hallmarked by a panoply of such
PRRs including C-type lectin receptors, RIG-like helicases and the
burgeoning understanding of Nod-like receptors (NLRs) as
sentinels of the intracellular environment [7].
Researchers in the emerging field of immune-engineering are
capitalizing on these exciting advances to open up the possibility to
direct and instruct immunological outcomes to a variety of
pathological conditions [8]. These include improving current
pathogen vaccines, to the more nascent fields of cancer
immunotherapy, tolerance induction in the setting of autoimmu-
nity and organ transplantation, as well as general immunological
rebalancing in diseased settings, such as the chronic inflammation
associated with type 2 diabetes. The implications of such
technology are profound and potentially represent a paradigm
shift in clinical practice across a broad swath of medicine.
However, efforts to use nanotechnology and material sciences
engineering to modulate human biology in situ require a
comprehensive understanding of the immune response, or lack
thereof, engendered to introduced nanocarriers [9,10].
In order for the gamut of potential downstream therapeutic
applications of nanomedicine to be realized, we must first
understand how the physical properties of nanomaterials augment
host immune responses. These principles will then enable the
appropriate design of nano- and micro-scale interventions for
specific purposes. For example, the use of nanoparticles to deliver
potent biological molecules, such as oligonucleotides or small
molecules augmenting intracellular signaling pathways, may
squander the regulatory opportunity to reach the clinic if the
nanocarriers for such entities initiate off-target events that activate
host immune responses. Conversely, vaccines can be made more
potent if nanocarriers are designed to activate the appropriate
innate immune response to tailor adaptive immune responses to
delivered antigens. As an example, the current state of the art is to
use Alum as a non-specific immunomodulatory adjuvant in
vaccine formulations. This could explain, in part, why some of
the most pressing pathogens do not yet have useful vaccines
because Alum is known to engender a mixed Th1/Th2-biased
humoral immune response that does not reflect the immune
activation which occurs during an actual microbial infection [11].
It is conceivable that nano-carriers designed to elicit the
appropriate adaptive immune response to an antigen of interest-
i.e., Th17 against fungal pathogens-may enable the generation of
vaccine-induced immune responses that more closely mimic the
natural immune response elicited by infection with a given
pathogen as opposed the non-tailored immunity induced by Alum.
A great issue in advancing nanotechnology from a laboratory
pursuit into a component of clinical care is a robust understanding
of how physical particle properties augment biological outcomes.
There is a wealth of literature promoting the use of nanotechnol-
ogy in modern medicine, but much of this literature relies on
particle fabrication methods, such as oil-in-water emulsion, that
generate heterogeneous populations of particles that can vary
widely between batches and across labs [12,13]. In addition, most
studies related to biomedical applications of nanotechnology have
not addressed the role of the immune system in the host response
to particulate delivery, a critical issue that threatens to diminish
the utility of such particles if these are rapidly cleared by innate
immune cells and/or induce localized or systemic immune
responses that pose unintended complications for clinical devel-
opment. In cases where the immunological parameters of
nanotechnology are being addressed, great variance is seen based
on size, composition and even surface modification of particles,
highlighting the tremendous complexity and exquisite sensitivity of
the immune system to nanoscale events [9,10,14].
Most currently employed fabrication methods do not allow
precise control over particle physical parameters, thus it is difficult
to draw conclusions as to how size, shape and composition affect
the innate immune response to particles in the nano and micron
range. To address this lack of knowledge, we employed our
recently developed top-down nanofabrication technique termed
Particle Replication in Non-Wetting Templates (PRINT) [15–18].
Using soft-lithography techniques adopted from the semi-conduc-
tor industry, PRINT enables the production of monodisperse
nano- and microparticles with well-defined control over particle
size, shape, composition, modulus and surface chemistry. There-
fore, the role of these physical parameters in augmenting biological
responses can be reproducibly probed using PRINT technology.
To lend both clinical and field relevance to our findings,
particles were designed with either the F.D.A approved polymer
Poly-lactic co-gloycolic acid (PLGA) or derivatives of the
commonly published hydrogel polymer polyethylene glycol
(PEG). While PLGA is an attractive polymer given its long history
of clinical use, our study was aimed in part to clarify discrepancy in
the literature as to whether particles made of PLGA trigger
inflammation. As our main purpose was to define the ‘baseline’
status of whether particles of defined size, shape and composition
triggered inflammation, we did not augment particles in this study
to include additional biologically active molecules, such as
oligonucleotides, small molecules or adjuvants as previously
published by our group and others [19–22]. To this end, we used
in vitro assays with murine derived macrophages and in vivo delivery
of particles to the lungs of mice to test the inflammatory potential
of these particles. The lung is a highly desired site for therapeutic
delivery of nanomedicine and we chose it for both clinical
relevance and its sensitivity as an immunological organ [23]. Our
findings imply that the delivery of PRINT nano- and micro-
particles do not engender systemic or localized inflammatory
responses and may not be impeded by host immune responses to
the polymers used in this study. Future design strategies for the
panoply of therapeutic opportunities made available by nanoen-
ginneering are likely available, as particles across broad size ranges
can thus be rationally designed from an inert state.
Materials and Methods
Particle Materials
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-
aminoetheyl methacrylate hydrochloride (AEM), Diphenyl
(2,4,6-trimethylbenzoyl)-phoshine oxide (TPO), and poly lactic
co-glycolic acid (PLGA; 85:15 lactic acid/glycolic acid, MW = 55
000 g/mol) were purchased from Sigma-Aldrich. Tetraethylene
glycol monoacrylate (HP4A) was synthesized in-house as previ-
ously described [24]. Thermo Scientific Dylight 650 maleimide,
PTFE syringe filters (13 mm membrane, 0.220 mm pore size),
dimethylformamide (DMF), triethanolamine (TEA), pyridine,
sterile water, borate buffer (pH 8.6), Dulbecco’s phosphate
buffered saline (DPBS) (pH 7.4), 1X phosphate buffered saline
(PBS) (pH 7.4), acetic anhydride and methanol were obtained
from Fisher Scientific. Conventional filters (2 mm) were purchased
from Agilent and polyvinyl alcohol (Mw 2000) (PVOH) was
purchased from Acros Organics. All PRINT molds used in these
studies (80 nm6320 nm, 1 mm cylinder, 1.5 mm and 6 mm donuts)
were kindly provided by Liquidia Technologies.
Murine Immune Response to Nano- and Microparticles
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e62115
PRINT PLGA Particle Fabrication
The PRINT process for fabricating particles has been described
previously [21,22]. Briefly, to fabricate PLGA particles, a
preparticle solution containing PLGA was prepared in a
DMSO/DMF/water solvent mixture (4:16:1) and cast on a
poly-(ethylene teraphthalate) (PET) sheet (delivery sheet) using a
#5 Mayer Rod (R.D. Specialties). The delivery sheet was placed
in contact with a PRINT mold with desired features patterned
(e.g., 806320 nm). The delivery sheet and mold were passed
through a heated laminator (150uC, 5.56105 Pa) and separated at
the nip. This heating process enables the PLGA polymer solution
to fill the molds, thereby forming nanoparticles of desired size and
shape. Nanoparticles were then harvested from the PRINT mold
by placing it in contact with a PET sheet coated with a layer
(400 nm cast from water) of poly(vinyl alcohol) (PVA,
MW = 2000 g/mol). This mold/PET-PVA ensemble was then
passed through the laminator (150uC, 5.56105 Pa) to transfer the
nanoparticles to the PVA sheet. Both laminator steps, the filling of
the mold and transfer of particles onto the PVA-coated PET sheet,
were performed at low humidity (,20–30%). Particles were
released from the PET/PVA sheet by delivering ,1 ml of sterile
water via a bead harvester to dissolve the PVA layer and remove
the particles from the PET sheet. A typical yield of 806320 nm
PLGA particles was ,0.4 mg particles/ft of PRINT mold, though
this depended on the particle feature size of the mold. To remove
excess PVA and concentrate the particles, tangential flow filtration
(TFF; Spectrum Labs) was used to concentrate particles in sterile
water (1–2 mg/ml). For later use in particle characterization
assays and experiments, particles were lyophilized by adding 106
mannitol and 86sucrose (106and 86to mass of particles) using a
tree lyophilizer. Mannitol and sucrose were used as cryoprotec-
tants.
PRINT Hydrogel Fabrication
The process of fabricating 806320 nm hydrogel particles was
conceptually similar to PLGA fabrication, but with important
differences. The pre-particle solution (PPS) contained a composi-
tion of 67.5 wt% HP4A, 20 wt% AEM (functional monomer),
10 wt% PEG700DA (crosslinker), 1 wt% TPO (photo initiator) and
1.5 wt% Dylight 650 maleimide. This composition was then
dissolved at 3.5 wt% in methanol and drawn as a thin film using a
# 3 Mayer rod (R.D. Specialties) onto a roll of corona treated
PET using an in-house custom-made roll-to-roll lab line (Liquidia
Technologies) running at 12 ft/min. The solvent was evaporated
from this delivery sheet by exposing the film to heat guns. The
delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned
side of the mold, followed by delamination at the nip. Particles
were cured by passing the filled mold through a UV-LED
(Phoseon, 395 nm, 3 SCFM N2, 12 ft/min). A PVOH harvesting
sheet was hot laminated to the filled mold (140uC, 80 PSI, 12 ft/
min). Upon cooling to room temperature, particles were removed
from the mold by splitting the PVOH harvesting sheet from the
mold. Particles were then harvested by dissolving the PVOH in a
bead of water (1 mL of water per 5 ft of harvesting sheet). The
particle suspension was passed through a 2 mm filter (Agilent) to
remove any large particulates. To remove the excess PVOH,
particles were centrifuged (Eppendorf Centrifuge 5417R) at
14000 rpm for 15 min, the supernatant was removed and the
particles were re-suspended in sterile water. This purification
process was repeated 4 times prior to lyophilization as detailed
above. The 806320 nm particles were acetylated prior to
experimental use to match negative charge of micron sized
hydrogel particles.
The 1.5 and 6 mm donut shaped hydrogel particles were
fabricated using a dropcast method. The pre-particle solution
(PPS) was composed of 20% PEG700-DA, 78% HP4A, 1% TPO
(photoinitiator), and 1% Dylight 650. The solution was spread
onto a fluorocur mold and a poly(ethylene terephthalate) (PET)
sheet was laminated on top of the mold and polymer mixture and
run through a heated, pressurized laminator to fill the molds. The
mold was then cured with a UV LED lamp for 30 seconds.
Particles were transferred out of the mold onto a Luvitec
harvesting layer by laminating the mold and Luvitec sheet
together and running them through a heated laminator nip. The
mold and harvesting sheet was separated, leaving free particles on
the harvest layer. Particles were collected from the harvest sheet by
bead harvesting with water and pelleted by centrifugation. The
particles were re-suspended in tert-butanol and lyophilized
overnight.
Particle Characterization
Thermogravimetric analysis (TGA) was used to determine stock
particle concentrations (TA Instruments Q5000 TGA). Briefly,
20 mL of the stock nanoparticle solution was pipetted into a tared
aluminum sample pan. The sample was heated at 30uC/min to
130uC and held at this temperature for 10 minutes. The sample
was then cooled at 30uC/min down to 30uC and held for 2
minutes. A Hitachi S-4700 scanning electron microscope (SEM)-
was used to visualize particles. Prior to imaging, the SEM samples
were coated with 1.5 nm of gold-palladium alloy using a
Cressington 108 auto sputter coater. Particle size and zeta
potential were measured by dynamic light scattering (DLS) on a
Zetasizer Nano ZS (Malvern Instruments, Ltd.).
Experimental animals
All studies were conducted in accordance with National
Institutes of Health guidelines for the care and use of laboratory
animals and approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of North Carolina at
Chapel Hill. All animals were maintained in pathogen-free
facilities at the University of North Carolina at Chapel Hill.
In vitro confocal analysis of hydrogel particle uptake
MH-S murine alveolar macrophages were plated in complete
DMEM at 20,000 cells per well in 8-well chamber slides (LabTek)
48 hours prior to treatment with particles. Particles were
resuspended in DMEM at 20 mg/ml and 300 ml of particle
solution were added to each well. Particles were incubated with
cells at 37uC for 4 hours. Cells were then washed twice with PBS
and cells fixed with 4% Paraformaldehyde (PFA) solution and later
stained with Alexa Fluor 488 Phalloidin (Invitrogen) and DAPI
(Vectashield, Vector Labs). Fluorescent imaging of stained cells
was performed on a Zeiss 710 laser scanning confocal imaging
system (Zeiss).
In vitro inflammation assays
Bone marrow macrophages were isolated from the femurs of
C57Bl/6 and BALB/c mice using standard procedures. Bone
marrow-derived macrophages were cultured for six days in
DMEM supplemented with 10% fetal bovine serum, L-Gluta-
mine, pen/strep and 20% L929-conditioned medium prior to use
in particle experiments. Adherent cells were isolated and plated in
complete Dulbecco’s Modifed Eagle Medium (Gibco) with 10%
fetal calf serum, 1% penicillin/streptomycin and 1% L-glutamine
at 200,000 cells per well in a 96-well dish for 24 hours prior to
treatment with particles for up to 24 hours. Some cells were
Murine Immune Response to Nano- and Microparticles
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primed with LPS (50 ng/ml) for 24 prior to particle treatment to
provide signal 1 for inflammasome activation. Monosodium urate
(MSU; Invivogen) treated at 300 mg/ml or ATP (5 mM; Sigma-
Aldrich) was used as a positive control for inflammasome
activation. Particles were resuspended in PBS prior to dosing at
various concentrations. After 24 hours of particle treatment in
triplicate, supernatants were harvested and analyzed by murine
IL-1b, TNF-a and IL-6 ELISA (BD Biosciences). Limit of
detection for ELISAs was 31.3 pg/ml (IL-1b) and 15.6 pg/ml
(TNF-a and IL-6). Lactate dehydrogenase release was used to
measure particle-induced cytotoxicity (Roche Applied Sciences).
Assessment of airway inflammation
To assess whether PRINT particles induce airway inflamma-
tion, 10–12 week old female C57Bl/6 mice were anesthetized with
isofluorane inhalation and particles were instilled via intratracheal
(i.t.) administration. 50 mg of particles were dosed in 50 ml of PBS.
Intratracheal administration of PBS (50 ml) or LPS (20 mg in 50 ml
PBS) served as negative and positive controls for airway
inflammation, respectively, as previously described [25]. Mice
were euthanized and airway inflammation was assessed 48 hours
or 7 days post treatment.
Serum was collected from animals by cardiac puncture and
centrifuged at 15,000 RPM for 10 minutes. The serum superna-
tant was collected and used for ELISA analysis of inflammatory
markers. Bronchoalveolar lavage fluid (BALF) was also collected to
evaluate local leukocyte and cytokine levels in the lungs. For this
purpose, lungs were lavaged three times with 1 ml Hanks
Balanced Salt Solution (HBSS; Gibco). After centrifugation at
1500 RPM for 5 minutes, cell-free supernatants were collected and
used to assess cytokine levels of IL-1b, TNF-a and IL-6 via ELISA
(BD Biosciences). RBC were lysed via brief hypotonic saline
treatment and the cell pellet was resuspended in PBS. Total BALF
cellularity was assessed with a hemacytometer. The cellular
composition was determined by cytospin of BALF aliquots onto
slides and staining with Diff-Quik (Dade Behring) for differential
cell counts. Leukocytes were identified based on the morphology
of $200 cells per sample. Following BALF harvest, the lungs were
fixed by inflation (20-cm pressure) and immersed in 10% buffered
formalin.
Histopathological examination
Inflammation was evaluated in 5 mm sections of the left lung
lobe after hematoxylin and eosin (H&E) staining. Serial paraffin-
embedded sections were set and cut to reveal maximum
longitudinal visualization of the intrapulmonary main axial airway
and inflammation was scored by one of the authors (I.C.A.) who
was blinded to genotype and treatment. As previously described,
histology images were evaluated on each of the following
inflammatory parameters and scored between 0 (absent) to 3
(severe): mononuclear cell infiltration, polymorphonuclear cell
infiltration, airway epithelial cell hyperplasia/injury, extravasa-
tion, perivascular cuffing, and estimated percentage of the lung
involved with inflammation [26,27]. Scores for each parameter
were averaged for a total histology score.
Particle uptake in BALF
BALF aliquots from PEG treated mice were fixed in 2%
paraformaldehyde and stained with DAPI (nuclei) and Phalloidin
488 (actin) and then viewed via epifluorescence microscopy for
particle uptake (Dylight 650). Five distinct fields of view (FOV)
were captured for each slide. The percentage of cell uptake was
determined by dividing the number of cells showing particle
internalization by the total number of cells in each field of view.
Statistical Analysis
GraphPad Prism 5 software was used to identify statistical
significance. Single data point comparisons were evaluated by
Student’s two-tailed t-test, whereas multiple comparisons were
evaluated for statistical significance using Analysis of Variance
(ANOVA) followed by Tukey-Kramer HSD post-test. All cytokine
and cell count data are presented as mean +/2 standard deviation
(SD) or standard error of the mean (SEM), respectively, with a p-
value less than 0.05 considered statistically significant.
Results
PRINT enables the fabrication of monodisperse and
homogenous particles
We employed Particle Replication in Non-Wetting Templates
(PRINT) in an effort to address whether particles of defined size,
shape and composition trigger an inflammatory response in mice.
This fabrication platform enables production of homogenous and
monodisperse particles with user-defined physical parameters. As a
large amount of literature shows crucial biological differences
depending on size and shape, the PRINT technique enables
reproducible probing of basic cell biology with nearly complete
control of design parameters [10,28–30].
For the purposes of our studies, we fabricated particles across
the nano and micron range to reflect biologically relevant sizes.
These include 806320 nm particles (commensurate with the sizes
of small bacteria and large viruses), 1 mm and 1.5 mm particles
(commensurate with bacteria and platelets), and 6 mm particles
(akin to a red blood cell in size) [28,31]. To characterize the
fabricated particles, we performed dynamic light scattering (DLS)
and zeta potential measurements as shown in Figure 1A. Note that
DLS measurements are quantified based on particles with a
perfect sphere shape, so that the size ranges detected are in line
with non-spherous shapes of the molds used. The poly-dispersity
index (PDI), a measure of heterogeneity in a particle population,
indicates we were able to fabricate monodisperse particles of the
same size and shape. This is further evidenced by scanning
electron microscopy images (Figure 1B). As the surface charge of
particles has been shown to play a role in biological outcomes,
such as protein adsorption and cell uptake, we measured the Zeta
potential of particles to quantify net surface charge [30,32,33]. For
all PLGA particles, surface charge was negative and decreased
with increasing particle size (Figure 1A).
While our initial studies used particles fabricated from the
F.D.A-approved biocompatible and biodegradable polymer poly(-
lactic-co-glycolic acid) PLGA, we also incorporated studies using
hydrogel particles fabricated with derivatives of biocompatible
poly (ethylene glycol) (PEG). Chemical modification of PEG is
more feasible than with PLGA and thus it is often used to add
increased functionality to nanocarriers, such as decoration of cell-
targeting ligands, imaging agents, and pharmacologic cargo
incorporation. Characteristics of fabricated PEG particles were
similar to that of the PLGA particles, with low PDI and negative
surface charge (Figure 1C) and monodisperisty as evidenced by
SEM (Figure 1D). These PEG particles were fabricated with a dye
(DyLight 650) to enable fluorescent imaging of particles in
downstream assays and may also be referred to as hydrogels
hereafter. To validate hydrogel particle uptake in a pertinent
pulmonary immune cell population, we performed confocal
analysis using the MH-S murine alveolar macrophage cell line.
As shown in Figure 1E, all particle sizes are taken by four hours
after treatment.
Murine Immune Response to Nano- and Microparticles
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PLGA particles do not induce inflammation by bone
marrow-derived macrophages
Much work has been done in vitro to assess the potential use of
PLGA nanoparticles in a variety of therapeutic modalities, from
delivery of chemotherapeutics and siRNA to imaging agents for
improved diagnostics. However, less work has been done to
characterize the innate immune response to such particles and
whether physical parameters of particles can augment the immune
response. As a primary sentinel of host homeostasis, the innate
immune system is tasked with identifying foreign matter in the
body and initiating an appropriate response. Subsequent activa-
tion of the innate immune response is hallmarked by release of
soluble protein messengers like cytokines that serve to recruit other
immune cells to the area to participate in defense and repair of the
host [7]. This inflammatory response is initiated by release of pro-
inflammatory cytokines, including TNF-a, IL-6 and IL-1b, from
innate immune cells, such as macrophages.
The field of environmental toxicology has long studied the role
of nanoparticulates in inducing inflammation, in particular in the
lung [34]. Attempting to synthesize work by other groups using a
range of particle compositions and sizes suggest that there is no
clear correlation between the physical parameters of a particle and
the ensuing inflammatory response to it. Generally speaking, the
composition of a particle has greater bearing on the inflammatory
response than its size or shape. As an example, titanium dioxide
and silica dioxide nanoparticles trigger inflammation, whereas zinc
oxide nanoparticles do not, even though all particles were of
Figure 1. PRINT Particle Characterization. A) Dynamic light scattering (DLS) and zeta potential measurements of PLGA particles used in studies.
Particle charge decreases with increasing size. B) Scanning electron microscope (SEM) images of PLGA particles. C) PEG particle composition and
characterization. D) SEM of PEG particles. E) Confocal images of hydrogel particle uptake in MH-S alveolar macrophage cells after 4 hours of
treatment. Scale bar is 50 mm.
doi:10.1371/journal.pone.0062115.g001
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Figure 2. PRINT particles do not cause inflammation in bone marrow-derived macrophages from BALB/c or C57BL/6 mice. A)
Overnight stimulation with a panel of PRINT PLGA and hydrogel particles (PEG) at 100 mg/ml does not cause TNF-a, IL-6, or IL-1b release from bone
marrow-derived macrophages from C57BL/6 mice as measured by ELISA. B) Both PLGA and hydrogel PRINT particles (PEG) tested negative for
endotoxin contamination using a Limulus amebocyte lysate assay. C) PRINT particles are not cytotoxic in bone-marrow derived macrophages as
determined by lactate dehydrogenase (LDH) release. D) 806320 nm PLGA particles do not synergize with LPS to induce inflammasome activation as
measured by IL-1b ELISA in BALB/c bone-marrow derived macrophages. E) Neither 806320 nm nor 1 mm PLGA particles synergize with LPS to induce
Murine Immune Response to Nano- and Microparticles
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similar size (15–20 nm) [35]. Others have identified size-depen-
dent inflammation and cell death that could be inhibited simply
with surface modification of silica particles with common chemical
groups such as aldehydes [36–38]. These findings highlight the
sensitivity of the innate immune system as each particle may
engender unique responses depending on its size, shape and
composition.
We initially tested the inflammatory potential of PRINT
particles in an in vitro cell culture system with bone marrow-
derived macrophages from C57BL/6 mice. We used a panel of
PRINT particles that differed in composition and size (Figure 1).
After either a 5 hour or 24 hour incubation with a panel of
PRINT particles comprised of either PLGA or PEG derivatives,
we saw no detectable levels of any tested pro-inflammatory
cytokine (TNF-a, IL-6, IL-1b) across a range of doses (1–100 mg/
ml) (Figure 2A and data not shown). Lipopolysaccharide (LPS), a
cell wall component of gram-negative bacteria, was used as a
positive control for inflammation induction. The lack of cytokine
induction was in line with data from endotoxin assays indicating
our fabrication process was endotoxin-free (Figure 2B). In
addition, across all doses of particles tested, we did not observe
any particle-induce cytotoxicity as measured by LDH assay
(Figure 2C).
Given the recent discovery of the inflammasome as a mediator
of the innate immune response to particulate challenge, we also
sought to address whether PRINT-fabricated PLGA particles
could cause inflammasome activation [35,39,40]. The inflamma-
some is a multi-protein complex that is formed in response to
variety of environmental stimuli, including asbestos, silica and
monosodium urate crystals (MSU), that results in the activation of
caspase-1 and subsequent maturation and secretion of the pro-
inflammatory cytokines IL-1b and IL-18 [41]. As our initial results
did not indicate any particle induction of IL-1b (Figure 2A), we
next assessed whether priming macrophages with LPS would
cause particles to induce inflammasome activation. LPS priming is
thought to provide signal 1 to inflammasome formation by
upregulating the protein levels of pro-IL-1b and NLRP3, a main
component of the inflammasome complex [42,43]. As assessed by
IL-1b release, we did not see PLGA particle-induced activation of
the inflammasome in the presence or absence of LPS-priming
when tested in either BALB/c (Figure 2D) or C57BL/6
macrophages (Figure 2E). Importantly, we tested particles across
a range of doses (100 ng–3000 mg/ml) and sizes (806320 nm and
1 mm cylinders). These results suggest that PLGA particles across
the nano and micron range do not synergize with TLR ligands
(i.e., LPS) to induce inflammasome activation in vitro and lend
further credence to the use of PLGA particles for in vivo
applications.
PLGA particles do not induce lung inflammation
Bolstered by our in vitro findings, we next were interested in
whether PLGA particles could be delivered to the lungs of mice
without causing overt signs of immune activation as hallmarked by
inflammation. The lung was chosen as a highly sensitive mucosal
organ with clearly defined markers of inflammation that is the
sight of numerous therapeutically relevant diseases, from allergies
and asthma to chronic obstructive pulmonary disorder (COPD)
and respiratory infections by microbial pathogens such as
tuberculosis and influenza [23,44]. As such, therapeutic modula-
tion of lung biology is a highly desired clinical goal with relevance
to the vast majority of the human population. We used intra-
tracheal (i.t.) delivery to determine whether 806320 nm PLGA
particles (50 mg) caused inflammation in the lungs, with PBS
(50 ml) and LPS (20 mg) used as negative and positive controls,
respectively. Forty eighthours after i.t. installation, mice (n = 5 per
group) were harvested and lung inflammation was assessed via
field standards used in respiratory infection models [26,27].
Broncheoalveolar lavage fluid (BALF) cellularity indicated no
recruitment of immune cells to the lungs after particle treatment,
as cell numbers were no different than the PBS control (Figure 3A).
LPS-treated mice revealed a robust accumulation of leukocytes as
is expected during inflammatory responses. Assessing the compo-
sition of leukocyte populations in the BALF revealed no significant
recruitment of immune cells to the lungs of particle-treated mice.
Conversely, LPS-treated mice had high levels of both monocytes
and neutrophils, key mediators of the innate immune system’s
inflammatory response (Figure 3B).
While BALF cellularity is widely used as a marker of lung
inflammation, lung histopathology enables a deeper understanding
of inflammatory effects on the lung parenchyma. We examined
representative sections of histopathology slides of the main bronchi
of the left lobe to further delineate leukocyte infiltration around
lung vasculature, parenchyma and the large and small airways
(Figure 3C). Whereas LPS treatment caused a clear accumulation
of leukocytes throughout the lung, treatment with 806320 nm
PLGA particles showed no difference as compared to PBS controls
(Figure 3D). To further verify the non-inflammatory nature of
these particles, pro-inflammatory cytokine levels were assessed in
the BALF and serum of treated mice. No significant release of IL-
1b (Figure 3E) or IL-6 (Figure 3F) was seen in the BALF. Serum
measurements for these same cytokines and TNF-a were
undetectable (data not shown). In total, these results are in
agreement with our in vitro findings and suggest that 806320 nm
PLGA particles can be delivered to the lungs without causing
innate immune activation and inflammation.
PEG particles stably remain within the lungs for 7 days
without causing lung inflammation
To broaden the implication of our in vivo findings, we fabricated
a series of particles using PEG polymers and their derivatives
(hydrogels) that incorporated fluorescent dyes which enabled us to
track them in vivo over time after lung instillation. The hydrogel
particles ranged in size from 806320 nm to 1.5 mm and 6 mm as
characterized in Figure 1. In vitro experiments indicated they did
not elicit inflammatory cytokines or cell death from bone marrow-
derived macrophages (Figure 2). Using the same experimental
approach as outlined above, we instilled 50 mg of particles i.t. into
C57BL/6 mice and assessed lung inflammation at two time points,
48 hours and 7 days post-particle instillation. As shown in
Figure 4A, total BALF cellularity does not increase in the presence
of hydrogel particles as compared to PBS at 48 hours, which is in
marked contrast to LPS-induced cell recruitment to the lungs.
Breaking down the BALF cell types revealed a similar number of
monocytes in the lungs PBS and particle-treated mice, whereas
LPS-treatment induced a marked influx of both monocytes and
neutrophils. At 7 days post-particle treatment, there was no
significant increase in the total BALF cellularity or composition in
mice treated with any hydrogel particles (Figure 4C and 4D).
Histopathology analyses indicated neither lung architecture
disruption nor leukocyte infiltration into the lungs or airways of
inflammasome activation as measured by IL-1b ELISA in C57BL/6 bone-marrow derived macrophages. MSU was dosed at 300 mg/ml. *** = p,0.001.
Experiments were performed in triplicate. Data shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0062115.g002
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Figure 3. 806320 nm PLGA particles do not cause lung inflammation in mice. Mice were challenged with either 50 mg of 806320 nm PLGA
particles or 20 mg LPS i.t. and airway inflammation was assessed 48 hours post-challenge. A) Total cellularity of bronchoalveolar lavage fluid (BALF) in
treated C57BL/6 mice is no different after 48 hours than PBS-treated mice and is significantly less than the inflammatory cell recruitment seen in LPS-
treated mice. B) PLGA particle treatment does not induce any appreciable immune cell recruitment to the lungs of mice, as opposed to the
heightened levels of monocytes and neutrophils seen in the lungs of LPS-treated mice. C) Histopathology revealed no significant differences in lung
architecture between PBS- and 806320 nm PLGA particle-treated mice. This is in stark contrast to the airway occlusion and significant innate immune
cell recruitment seen in LPS-treated mice. D) Histopathology scoring confirmed that no significant differences were seen between the lungs of PBS
and PLGA particle treated mice. E–F) The increased lung levels of pro-inflammatory IL-1b and IL-6 seen in LPS-treated mice is not found in PLGA-
treated mice. PBS, n = 3; 806320 nm PLGA particle-treated, n = 5; LPS-treated, n = 3. ND = Not Detected. * = p,0.05, *** = p,0.001. Experiments were
performed using 3–5 mice per group. Data shown are representative of at least two independent experiments.
doi:10.1371/journal.pone.0062115.g003
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particle-treated mice as compared to PBS controls at either the
48 hour or 7 day time point (Figure 4E and 4F).
Remarkably, and despite the absence of overt signs of
inflammation, 6 mm particles with their hallmark donut appear-
ance could be viewed within the lung spaces of multiple mice by
H&E staining 2 and 7 days post-challenge (Figure 5A–B). The lack
of immune cell recruitment or disruption of tissue architecture
around these particles may suggest an immunologically inert
deposition of particles within the alveolar spaces. Such a depot
may provide sustained localized delivery of therapeutically
attractive molecules. Because the 806320 nm and 1.5 mm
particles were too small to see in lung histology samples, we also
performed immunofluorescence imaging on BALF samples to
determine whether lung-localized cells took up particles. As shown
in Figure 5C, BALF cells contained hydrogel particles of all sizes at
48 hrs (magnified view in Figure 5D). We also noted that the
percentage of cells with particles decreases as particles size
increases (Figure 5E). Whether this is due to the quantitatively
higher number of 806320 nm particles at the same dose weight of
larger particles, the relatively easier ability for a cell to take up
smaller particles as compared to larger ones, or an as yet
unidentified size-dependent biological effect remains unanswered.
We were also interested to find that BALF cells 7 days after
particle instillation show particle uptake, albeit to a lesser extent
than the 48 hour time point (Figure 5F and magnified view in
Figure 5G). Finally, we quantified the levels of pro-inflammatory
cytokines released into the BALF and serum of PEG particle-
treated mice. At both the 48 hour and 7 day time points we were
unable to detect IL-1b, IL-6, or TNF-a for any particle treatment
(data not shown). In total, these data highlight the ability of
PRINT particles to remain localized to the lung for long periods of
time in an immunologically inert manner.
Discussion
Given the diverse therapeutic potential of nano- and microscale
particles, this study sought to define whether particles composed of
either PLGA or PEG-derivatives induced inflammatory responses
in an in vitro and in vivo setting. By making use of the highly
controlled PRINT fabrication method, we were also able to
determine whether particle size affected any ensuing innate
immune responses. Our findings reveal that PRINT particles do
not cause any obvious activation of the innate immune response in
murine macrophages or the murine lung and maintain long term
(7 day) immunologic stability in the lungs of mice.
The wide array of polymers and particle fabrication techniques
used in nanomedicine studies makes it difficult to reach definitive
conclusions regarding particle effects on innate immune functions.
We initially used particles fabricated from PLGA as this is a
commonly used polymer with attractive clinical potential given its
F.D.A approval. There is some discrepancy in the literature as to
whether PLGA particles are inflammatory in situ. Some groups
suggest PLGA particles are inflammatory in vitro and in vivo,
whereas others have not found this to be the case [39,45–48]. Our
study reveals that PLGA particles of nano and micron range
fabricated by PRINT technology do not synergize with a TLR
ligand to cause inflammasome activation nor inflammation in
general, and that in vivo delivery does not trigger an inflammatory
reaction, contrary to a previous report [39]. The discrepancy
between these findings may be due to differences in particle
fabrication or experimental settings [49]. However, given the long
clinical history of PLGA and the broad literature reporting PLGA
particle uses for biomedical applications, it seems unlikely that
particles derived from PLGA would trigger potent inflammatory
responses, yet this confusion is precisely why more research must
be carried out to ensure such unwanted side-effects are avoided as
fabrication methods or material sourcing may impact immune
responses significantly [50–52].
In addition, our studies using PEG particles enabled us to
broaden our understanding of innate immune activation by
particles comprised of a polymer composition that enables wide-
ranging chemical modifications for enhanced functionality, such as
cell targeting, pH-specific cargo release and siRNA incorporation
as previously reported by our group and others [19,20,53,54].
Interestingly, although these PEG particles are not considered
biodegradable, they did not induce lung inflammation as seen with
other non-degradable particles such as those comprised of
polystyrene [46]. This suggests our PEG polymer composition
may also be an attractive alternative from an environmental
toxicology perspective in applications currently employing poly-
styrene particles.
The issue of innate immune activation by particles is of central
relevance to the translational application of nanotechnology.
While particulate vaccines against some pathogens and cancers
will likely be designed to trigger localized inflammation as part of
the general innate immune activation required for robust adaptive
immune responses, most other biomedical applications for nano-
and microparticles will benefit by avoiding such responses.
Additionally, a strong immune response might lead to the
undesirable outcome of rapid particle clearance as well as
hypersensitivity responses. Drug delivery, diagnostic imaging and
physiological bio-mimicry are examples of nanoengineering
applications that may be impeded by innate immune activation.
Importantly, many advances in immune modulation made
available through rationally designed nano- and microscale
particles such as tolerance induction in the setting of autoimmu-
nity or organ transplantation, direct targeting of immune cell
subsets and immune-skewing of pathological microenvironments
such as tumors or sites of chronic inflammation, require that
particles be designed initially from an inert immunological state
[55–61]. To wit, if particles alone trigger inflammatory responses
that skew towards any type of adaptive response (e.g., Th1, Th2)
then many of these therapeutic goals will not be achieved. For
these reasons, we feel it is of utmost importance that baseline
innate immune responses to particles be assessed as part of field
standards [9].
Our in vivo studies reveal that particle size augments uptake into
innate immune cells of the lungs, with larger particles taken up less
than smaller particles. This finding suggests a duality in design
considerations depending on therapeutic application. For exam-
Figure 4. Hydrogel particles do not cause lung inflammation in mice. Mice were challenged with 50 mg of hydrogel particles (806320 nm,
1.5 mm, or 6.0 mm donuts) i.t. and airway inflammation was assessed 48 hours and 7 days post-challenge. A) BALF analysis indicated no increased
cellularity 48 hours after hydrogel particle treatment, whereas a significant cellular influx was seen in LPS-treated controls. B) At 48 hours, BALF
cellular composition does not show any significant trend for immune cell recruitment in hydrogel particle-treated mice. C–D) BALF cellularity and
composition was not significantly augmented seven days after hydrogel particle treatment. E) Histopathology analysis revealed no significant
differences in lung architecture between PBS- and hydrogel particle-treated mice at either 2 or 7 days post-treatment. F) Histopathology scoring
confirmed that no significant differences were seen between the lungs of PBS and hydrogel particle treated mice at any time points. *** = p,0.001.
Experiments were performed using 2–5 mice per group. Data shown are representative of at least two independent experiments.
doi:10.1371/journal.pone.0062115.g004
Murine Immune Response to Nano- and Microparticles
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e62115
Figure 5. Hydrogel particles remain in the lungs for multiple days without overt signs of inflammation. A) 6 mm hydrogel particles
(denoted by red arrows) are visible in the alveolar spaces 2 days after intratracheal installation. Lower insets are a magnified view of black bounding
box. PBS treated mice are shown as control. B) Multiple 6 mm hydrogel particles (denoted by black bounding box and red arrows) are visible in the
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ple, drug delivery to the lungs to ameliorate asthma would likely be
best served by larger particles that can release their cargo to
extracellular spaces. Conversely, if trying to deliver a respiratory
vaccine, smaller particles that are more readily taken up by
antigen presenting cells and traffic to lymph nodes would be more
appropriate. Our finding that particles of all tested sizes remain in
the lungs up to 7 days post instillation also suggest the ability to
provide sustained localized delivery of therapeutically attractive
molecules via particulate formulations. This is far different than
the rapid clearance seen for smaller particles (,50 nm diameter)
and reflects the importance of particle design parameters when
considering therapeutic interventions [62].
The lung serves as an attractive route for therapeutic delivery
due to its ease of access and its large absorptive surface area. There
are several important particle characteristics that need to be
considered for effective pulmonary delivery such as size, shape,
surface charge, toxicity, and potential inflammatory effects.
Inhaled particles with mass median aerodynamic diameters
(MMAD) larger than 5 mm tend to be deposited in the upper
conducting airway while particles with MMAD between 1–5 mm
deposit in the lower respiratory airways [63]. Using PRINT, we
have the ability to design particles with aerodynamically relevant
deposition characteristics while having distinct non-spherical
geometries enabling different deposition profiles in the lung
[64,65]. The investigation of the safety profile and inflammatory
response of these inhaled polymeric particles is important to
support their use as drug delivery vehicles as highlighted in this
study.
Having identified particles across the nano- and microscale that
do not trigger inflammatory responses in mice while remaining in
the lungs, we plan to next use these particles as delivery devices for
a range of biologically relevant molecules, including siRNAs, anti-
inflammatory agents, and immune-skewing compounds. It should
also be noted that mucoadhesive components may be incorporated
within the PRINT particle system to enhance adsorption in the
mucosal region which may enable differential deposition and
enhanced temporal localization to the lungs. These studies will test
the hypothesis that targeted modulation of lung immunology via
nanoengineering may enable a new class of therapeutics for lung
disorders that avoid systemic side-effects while also reducing
administration doses. While we have tested a 50 mg dose of inert
particles in this manuscript, PRINT enables a high weight percent
loading of bioactive molecules and thus local and sustained
pulmonary delivery may show therapeutic efficacy at low particle
doses [19–22,66–68].
Importantly, we will move studies into human cells to provide
much needed data regarding the immunological response to
nanomaterials in our own species. Using the design control
inherent to PRINT technology, we will also be able to
systematically address the role of particle size and shape during
delivery of bioactive molecules. Such results may be crucial to
advancing next-generation respiratory vaccines and treatments for
asthma, allergies and chronic disorders of lung function.
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